Brought to you by:
Philips announces positive two-year data from TOBA II BTK clinical trial
Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial. The data show the Philips Tack endovascular system (4F), a first-of-its kind dissection repair device, provides a sustained treatment effect and positive…
Stenting found to be superior to atherectomy, balloon angioplasty in reducing PAD mortality risk
Stenting reduced mortality risk in patients undergoing interventions for peripheral arterial disease (PAD) by more than 30% when compared to plain balloon angioplasty, and 40% contrasted with atherectomy, a recent propensity-matched analysis found. The Vascular Quality Initiative (VQI)-derived data drew…
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been published in the Journal of Vascular Surgery. Results showed sustained positive outcomes for both amputation-free survival and…
ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices
Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky, MD, an interventional cardiologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, reported this conclusion…
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in PAD patients
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease (PAD) who underwent lower-extremity revascularization, according to researchers conducting the VOYAGER PAD trial. The findings were…
Intermittent claudication and exercise therapy: A poor SET-up
Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery colleagues. In case you haven’t, this is your chance to catch up and to prepare for…
The top 10 most popular stories from April
Our April cover story on the links between electronic health records (EHRs) and physician burnout, the continuing problem of manels (or all-male speaking panels) at vascular surgery meetings, and some of the latest details on the 2021 Vascular Annual Meeting…
MicroStent to treat PAD below the knee receives FDA breakthrough device designation
Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed to achieve and maintain vessel patency, enhance wound treatment and improve quality of life and blood…
Interventions associated with ‘poor’ two-year relief of intermittent claudication symptoms
Peripheral vascular interventions for intermittent claudication were linked to “poor” two-year relief of symptoms in the Vascular Quality Initiative (VQI) database, a new study published in the May issue of the Journal of Vascular Surgery (JVS) found. First-named author Jonathan…
SoundBite peripheral crossing system gains FDA approval
Soundbite Medical Solutions has announced Food and Drug Administration (FDA) 510(k) approval for the SoundBite crossing system—Peripheral (SCS-P) with the 0.014” active wire (14P). The SoundBite crossing system—Peripheral (14P) is a recanalization tool, designed to help physician’s placement of conventional…